NCT06831825View on ClinicalTrials.gov

Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 23, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
COMBINATION_PRODUCT

YAP101 (AAV9-Sav-shRNA)

YAP101 delivered using YAPCATH-101

Trial Locations (1)

77030

RECRUITING

Texas Heart Institute, Houston

All Listed Sponsors
lead

YAP Therapeutics, Inc.

INDUSTRY